Lexaria Bioscience Corp. (NASDAQ: LEXX) Focused on Filling Need for Hypertension Treatment Solution

Rhea-AI Summary

Lexaria Bioscience Corp. (NASDAQ: LEXX) announced a new broadcast titled, "The Power of Science to Stop a Killer," focusing on its patented drug-delivery technology, DehydraTECH(TM). This innovation enhances the absorption of active pharmaceutical ingredients (APIs), potentially addressing the global anti-hypertensive market, valued at $24.17 billion in 2020 and projected to reach $27.81 billion by 2025. Hypertension contributes to significant healthcare costs, estimated at $131 billion annually in the U.S., with over 670,000 related deaths in 2020.

Positive

• DehydraTECH significantly improves API absorption by 5-10 times.
• The technology reduces onset time from hours to minutes.
• Robust patent portfolio with 25 patents granted and over 50 pending.

Negative

• None.

NEW YORK, Aug. 11, 2022 (GLOBE NEWSWIRE) -- NetworkNewsAudio – Lexaria Bioscience Corp. (NASDAQ: LEXX) announces the availability of a broadcast titled, “The Power of Science to Stop a Killer.”

To hear the AudioPressRelease, please visit: The NetworkNewsAudio News Podcast

To view the full editorial, please visit: https://nnw.fm/9kD5b

In its 2021 industry report, ReportLinker estimated the global anti-hypertensive drugs market at $24.17 billion in 2020 on its way to reach $27.81 billion in 2025. All told, hypertension costs the country on average $131 billion annually, and even more sobering, in 2020 alone, more than 670,000 deaths in the United States had hypertension as a primary or contributing cause.

A recognized global innovator in drug-delivery platforms, Lexaria Bioscience Corp. (NASDAQ: LEXX) is determined to fill the need for a safe, effective, tolerable treatment for hypertension and have a meaningful impact on comorbidity-related costs and deaths. Its patented flagship product, DehydraTECH(TM), improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules. DehydraTECH promotes fast-acting, less expensive, and more effective oral drug delivery and has been thoroughly evaluated through in vivo, in vitro and human clinical testing.

About Lexaria Bioscience Corp.

Lexaria’s patented drug delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bioabsorption with cannabinoids and nicotine by up to five to ten times, reduce time of onset from one to two hours to minutes, and mask unwanted tastes; the innovative tech is also being evaluated for orally administered anti-viral drugs, nonsteroidal anti-inflammatory drugs (“NSAIDs”), PDE5 inhibitors and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 25 patents granted and more than 50 patents pending worldwide.

For more information about the company, please visit www.LexariaBioscience.com. 

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX 

About NetworkNewsWire

NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the InvestorBrandNetwork

FAQ

What is Lexaria Bioscience Corp.'s focus area?

Lexaria Bioscience Corp. focuses on developing innovative drug-delivery technology, specifically DehydraTECH, to improve the efficacy of medications.

What is DehydraTECH?

DehydraTECH is Lexaria's patented technology that enhances the absorption of active pharmaceutical ingredients, making oral drug delivery more effective.

How much is the anti-hypertensive drug market expected to grow?

The global anti-hypertensive drug market is projected to grow from $24.17 billion in 2020 to $27.81 billion by 2025.

What healthcare costs are associated with hypertension in the U.S.?

Hypertension costs the U.S. approximately $131 billion annually, contributing to over 670,000 deaths in 2020.

Where can I listen to Lexaria's latest broadcast?

You can listen to Lexaria's latest broadcast titled, "The Power of Science to Stop a Killer," through their NetworkNewsAudio podcast.